Teaneck-based Phibro Animal Health Corporation officially announced a planned leadership transition designed to anchor the company’s long-term strategic growth. Effective July 1, 2026, longtime leader Jack Bendheim will transition to the role of executive chairman, while Daniel (Dani) Bendheim will step up as the company’s new chief executive officer and president.
The move marks a significant milestone for the global animal health and nutrition leader, ensuring continuity within the founding family’s leadership while positioning the firm for its “next chapter” of international expansion.
Jack Bendheim’s tenure at Phibro spans over five decades. Having joined the company in 1969, he has served as president since 1988 and took the mantle of CEO in 2014. Under his guidance, Phibro evolved from a niche player into a global powerhouse in the livestock and nutrition sectors.
In his upcoming role as executive chairman, Jack will remain chairman of the board and continue to provide strategic oversight, focusing on long-term growth initiatives and supporting the executive team.
“As Phibro continues to evolve and expand, this is the right moment to transition leadership,” Jack Bendheim said. “Dani brings deep knowledge of our business, strong operational discipline, and a global perspective that aligns with the future of our industry.”
Dani Bendheim is no stranger to the inner workings of Phibro, having been with the company since 1997. His path to the CEO position has been paved by nearly 30 years of diverse leadership roles:
-
1997: Joined Phibro Animal Health.
-
2001: Appointed VP of Business Development.
-
2004: Named president of Performance Products.
-
2014: Promoted to executive VP of Corporate Strategy.
-
Recent: Served as chief transformation officer, leading the “Phibro Forward” initiative aimed at efficiency and cultural engagement.
“Phibro is in the best position it has ever been,” Dani Bendheim noted. “I look forward to continuing to work with our global leadership team… to advance our strategy, support our customers, and build on the Company’s momentum.”
The Board of Directors expressed unanimous support for the transition, emphasizing that the current executive leadership team will remain in place. This stability is intended to reassure investors and partners that Phibro’s core values and operational goals will remain consistent during the handover at the end of the 2026 fiscal year.
Phibro remains a leading partner for livestock producers and veterinarians worldwide, providing critical solutions for animal health, nutrition, and mineral specialties.
